Boston Scientific Corporation · NYSE:BSX
Boston Scientific — Q4 2005 Earnings Presentation
22 slides from Boston Scientific's earnings presentation, Feb 7, 2006
Slide 1: Delivering what's next
Sueunhe Delivering what's next.”
Slide 2: Safe Harbor: Forward-Looking Statements
Safe Harbor: Forward-Looking Statements SBeSt¢Mfic telease contains “forward-looking statements,” incl ‘statements, statements regarding the proposed business combi © Scientific Corporation and Guidant Corporation, and the Sie ee and benefits of such transaction. Statements made in the future tense,
Slide 3: Safe Harbor: Additional Information
Safe Harbor: Additional Information Coen Scientific and Guidant have filed a preliminary in connection with the proposed transaction. hot a substitute for the preliminary pro: nt Aocuments that Soston Selene apd cerdant Reve fled or wl fie : Investors and security holders are urged to read the preli
Slide 4: Worldwide Sales by Global Division
Worldwide Sales by Global Division Coen 2005 vs. 2004 — WORLDWIDE TOTAL. Cardiovascular Electrophysiology Neurovascular Oncology Endoscopy SUBTC 35 5,676 10 % 0% Neuromodulation 148 46 222% «222 %| WORLI
Slide 5: Worldwide Sales by Geography
Boston, Worldwide Sales by Geography Scientific 2005 vs. 2004 WORLDWIDE TOTAL Change EUROPE ' 994 JAPAN 613 INTER-CONTINENTAL
Slide 6: DES Revenue by Region
Boston, DES Revenue by Region Scientific 2005 vs. 2004 ~ =
Slide 7: Sales Bridge: 2005 vs. 2004 ($M)
Sales Bridge: 2005 vs. 2004 ($M) +193 4102 $5,624 2004 Neuromod. Endosurgery US DES +220 4 ous DES Other Boston, Scientific 2005
Slide 8: Financial Results (Excluding Special Charges)
Financial Results (exciuding special Charges) create Gross Margin SG&A R&D 3 569 18%) Royalties 195 crow} Amortization 112 am Operating Expense Bae Gre) Operating Income / ou Non Operating Expense (0) Inc Before Taxes / ee. «| Net Income EPS [s_ 163 2 ‘
Slide 9: Link to searchable text of slide shown above
Link to searchable text of slide shown above
Slide 10: Delivering what's next
Sean Delivering what's next.”
Slide 11: Financial Results (Excluding Special Charges)
Financial Results (Excluding Special Charges) Q4 2005 vs. Gross Margin Operating Expense Operating Income Non Operating Expense linc Before Taxes Net Income EPS Boston, Scienti fic
Slide 12: Sales Bridge: Q4 2005 vs. Q4 2004 ($M)
Sales Bridge: Q4 2005 vs. Q4 2004 ($M) —estone., 105 422 i | $4,540 2 Q4 2004 USDES OUSDES Neuromod. Endosurgery Other Q4 2008.
Slide 13: Delivering what's next
Serunhe Delivering what's next.”
Slide 14: Delivering what's next
Sean Delivering what's next.”
Slide 15: Accelerating Revenue Growth
Accelerating Revenue Growth Sheenhc Proforma Co (Oolars in Bitlons) | | | 2007E 2008E 2009E 2010E 2011E
Slide 16: Accelerating Proforma Adjusted EPS
Accelerating Proforma Adjusted EPS et Re $2.61 $2.24 2008E =. 2010E $3.13 CAGR 20%+ $1.98 $1.52 2007E 2008E 2011E
Slide 17: Basis of Reporting Moving Forward
Basis of Reporting Moving Forward _ Sete ‘oston Scientific will be reporting Adjusted EPS in | addition to GAAP EPS. Adjusted EPS is defined as: GAAP EPS excluding amounts related to: Effect of purchase price allocation on assets: write-off of in-process research and development samortization of ide
Slide 18: Accelerating Proforma Adjusted EPS
Accelerating Proforma Adjusted EPS et Re $2.61 $2.24 2008E =. 2010E $3.13 CAGR 20%+ $1.98 $1.52 2007E 2008E 2011E
Slide 19: Strong Proforma Operating Cash Flow
Strong Proforma Operating Cash Flow set 2007E 2008E 2011E
Slide 20: Next Chapter of Growth
Next Chapter of Growth Seestfic 16900 Strategic Build Continues cy Revenue ($M) pene nnan® tee ns Tne set teat tieoenod net tet OY comping HHH ODT RK 20 Note: Assumes 01101106 acquisition of Guidant
Slide 21: Adjusted EPS
Adjusted EPS pertne Boston Scientific provides adjusted net income and adjusted net income per share amounts in order to. provide meaningful supplemental information regarding its operational performance and its prospects for the future. These supplemental measures exclude the impact of certain char
Slide 22: Searchable text section of graphics shown above
Searchable text section of graphics shown above F iled by Boston Scientific Corporation Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Guidant Corporation Commission File No.: 001-13388 The fol